Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 19/20 | 0.81 |
| ▸ | MMP1 | P03956 | 16/20 | 0.81 |
| ▸ | MMP2 | P08253 | 13/20 | 0.81 |
| ▸ | MMP9 | P14780 | 9/20 | 0.81 |
| ▸ | MMP7 | P09237 | 5/20 | 0.81 |
| ▸ | MMP13 | P45452 | 4/20 | 0.81 |
| ▸ | MMP14 | P50281 | 1/20 | 0.81 |
| ▸ | MMP8 | P22894 | 1/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6554365 | 0.91 | MMP2 (0.67) | MMP3MMP1MMP2MMP9MMP7 | |
| Rebimastat SCHEMBL2379355 | 0.89 | MMP1 (1.00) | MMP3MMP1MMP2MMP9MMP7 | |
| Rebimastat SCHEMBL12247619 | 0.89 | MMP1 (1.00) | MMP3MMP1MMP2MMP9MMP7 | |
| Rebimastat SCHEMBL4826862 | 0.89 | MMP1 (1.00) | MMP3MMP1MMP2MMP9MMP7 | |
| Rebimastat SCHEMBL645121 | 0.89 | MMP1 (1.00) | MMP3MMP1MMP2MMP9MMP7 | |
| Rebimastat SCHEMBL12946005 | 0.89 | MMP1 (1.00) | MMP3MMP1MMP2MMP9MMP7 | |
| SCHEMBL7604548 | 0.88 | MMP3 (0.63) | MMP3MMP1MMP2MMP9MMP7 | |
| Rebimastat SCHEMBL12247626 | 0.86 | MMP1 (0.90) | MMP3MMP1MMP2MMP9MMP7 | |
| Rebimastat SCHEMBL12247617 | 0.83 | MMP1 (0.88) | MMP3MMP1MMP2MMP9MMP7 | |
| SCHEMBL12300383 | 0.82 | MMP1 (0.83) | MMP3MMP1MMP2MMP9MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040208924-A1 | Pharmaceutical tablet having a high api content | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | claimed |
| EP-0859784-B1 | THIO-SUBSTITUTED PEPTIDES AS INHIBITORS FOR METALLOPROTEINASES AND TNF LIBERATION | DARWIN DISCOVERY LTD (GB) | 2002-12-18 | — | — | EP | claimed |
| US-20040208924-A1 | Pharmaceutical tablet having a high api content | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | disclosed |
| US-20040175419-A1 | Control of compactibility through cystallization | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-09 | — | — | US | disclosed |
| US-5981490-A | ADMINISTERING A PEPTIDYL COMPOUND FOR TREATMENT IN A HUMAN OR ANIMAL OF A CONDITION ASSOCIATED WITH MATRIX METALIOPROTEINASES OR THAT IS MEDIATED BY TUMOR NECROSIS FACTOR ALPHA OR L-SELECTIN SHEDDASE | DARWIN DISCOVERY, LTD. (GB) | 1999-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040175419-A1 | Control of compactibility through cystallization | PKD1, PKD2, CALU | MMP3 2755/4885MMP1 564/4885MMP2 1871/4885 |
| US-20040208924-A1 | Pharmaceutical tablet having a high api content | TREH, SI, CYP3A5 | MMP3 3203/4885MMP1 3708/4885MMP2 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.